Abstracts tagged "Biologicals"

Abstract Number: 1208 • ACR Convergence 2020
Utility of Measuring the Immunogenicity to CT-P13 for Subcutaneous Use in Patients with Active Rheumatoid Arthritis: 1-Year Results from a Multicenter, Randomized Controlled Pivotal Trial
Rene Westhovens¹, DaeHyun Yoo², Piotr Wiland³, Marek Zawadzki⁴, Delina Ivanova⁵, Alfredo Berrocal Kasay⁶, Elias Chalouhi⁷, Eva Balázs⁸, SangJoon Lee⁹, SungHyun Kim⁹, JeeHye Suh⁹, ChanKyoung Hwang⁹ and DaeSeok Choi⁹, ¹University Hospitals Leuven, Belgium, Leuven, Belgium, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³Medical Univeristy, Wroclaw, Poland, ⁴Medical Univeristy, Dpt of Rheumatology , Wroclaw, Wroclaw, Poland, ⁵Diagnostic-Consultative Center Aleksandrovska EOOD, Sofia, Bulgaria, ⁶ABK Reuma SRL, LIMA, Peru, ⁷Clinica Internacional Sede Lima, Lima, Peru, ⁸Dr. Bugyi István Hospital, Szentes, Hungary, ⁹Celltrion, Inc., Incheon, Republic of Korea
Background/Purpose: Novel subcutaneous infliximab (CT-P13 SC) was developed to augment the flexibility in the therapeutic use of infliximab and non-inferiority (NI) of CT-P13 SC versus…
Abstract Number: 1366 • ACR Convergence 2020
Secukinumab Improved Signs and Symptoms in Patients with Non-radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study Stratified by Baseline Objective Signs of Inflammation
Juergen Braun¹, Ricardo Blanco², Helena Marzo-Ortega³, Lianne Gensler⁴, Filip Van den Bosch⁵, Hideto Kameda⁶, Denis Poddubnyy⁷, Marleen van de Sande⁸, Anna Wiksten⁹, Brian Porter¹⁰, Santiago Moreno⁹, Abhijit Shete⁹, Hanno Richards⁹, Sibylle Haemmerle⁹ and Atul Deodhar¹¹, ¹Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, 44649 Herne, Germany, ²Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ³The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ⁴University of California San Francisco, San Francisco, CA, ⁵Ghent University Hospital, Ghent, Belgium, ⁶Toho University, Tokyo, Japan, ⁷Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁸Amsterdam UMC, AMC/University of Amsterdam, Department of Rheumatology and Clinical Immunology, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Oregon Health & Science University, Portland, OR
Background/Purpose: Active non-radiographic axial spondyloarthritis (nr-axSpA) is often determined on the basis of objective signs of inflammation (elevated C-reactive protein [CRP] and/or evidence of sacroiliitis…
Abstract Number: 1745 • ACR Convergence 2020
A Novel Method for Predicting 1-Year Retention of Abatacept Using Machine Learning Techniques
Rieke Alten¹, Claire Behar², Christine Boileau², Pierre Merckaert², Ebenezer Afari², Virginie Vannier-Moreau³, Sean Connolly³, Yedid Elbez², Pierre-Antoine Juge⁴ and Karissa Lozenski³, ¹Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany, ²Excelya, Boulogne-Billancourt, France, ³Bristol-Myers Squibb Company, Princeton, NJ, ⁴Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France
Background/Purpose: In the ACTION (NCT02109666) study, using multivariable Cox proportional hazards regression models, patient (pt) global assessment of pain, country, reason for stopping last biologic,…
Abstract Number: 2028 • ACR Convergence 2020
Predictors of Maintaining Inactive Disease After Etanercept Withdrawal, and Regaining Inactive Disease Status After Flare and Retreatment, in Adults with Non-radiographic Axial Spondyloarthritis: Results from RE-EMBARK
Filip Van den Bosch¹, James Cheng-Chung Wei², Francisco Blanco³, Pamela Selema⁴, Daniela Graham⁵, Edmund Arthur⁶, Vassilis Tsekouras⁷, Bonnie Vlahos⁴, Chuanbo Zang⁴, Atul Deodhar⁸ and Peter Nash⁹, ¹Ghent University Hospital, Ghent, Belgium, ²Chung Shan Medical University Hospital, Taichung, Taiwan (Republic of China), ³INIBIC-Complejo Hospitalario Universitario A Coruña, A Coruna, Spain, ⁴Pfizer, Collegeville, PA, ⁵Pfizer, Groton, PA, ⁶Pfizer, Peapack, NJ, ⁷Pfizer, Nicosia, Cyprus, ⁸Oregon Health & Science University, Portland, OR, ⁹School of Medicine Griffith University, Brisbane, Queensland, Australia
Background/Purpose: RE-EMBARK was a phase 4, multicenter, open-label, 3-period study that evaluated etanercept (ETN) withdrawal and retreatment in adult patients with non-radiographic axial spondyloarthritis (nr-axSpA)…
Abstract Number: 0221 • ACR Convergence 2020
Should We Use BioDMARDS in First Intention in Early Rheumatoid Arthritis? : Results at 5 Years from the ERA Louvain Brussels Cohort
Emilie Sapart¹, Tatiana Sokolova¹, Stéphanie de Montjoye¹, Stéphanie Dierckx², Adrien Nzeusseu Toukap³, Aleksandra Avramovska¹, Laurent Meric de Bellefon¹ and Patrick Durez⁴, ¹Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCL) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ²Rheumatology, CHU Mont-Godinne, Mont Godinne, Belgium, ³1Department of Rheumatology, Cliniques Universitaires Saint Luc, 2Institut de recherche expérimentale et clinique (IREC), Brussels, Belgium, ⁴Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
Background/Purpose: Early effective treatment has led to major improvements in patients with rheumatoid arthritis (ERA). Low disease activity and remission are achieved earlier and in…
Abstract Number: 0351 • ACR Convergence 2020
Ustekinumab-Treated Patients with Psoriatic Arthritis in a Real-world Study: Similar Clinical Responses and Treatment Persistence over One Year in Elderly and Younger Patients
Laure Gossec¹, Elke Theander², Soumya Chakravarty³, Paul Bergmans⁴, Iris Lin⁵, Wim Noël⁶, Stefan Siebert⁷ and Josef Smolen⁸, ¹Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ²Janssen Cilag, Lund, Sweden, ³Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁴Janssen Biostatistics and Medical Affairs, Tilburg, Netherlands, ⁵Janssen Immunology Global Commercial Strategy Organization, Horsham, ⁶Janssen Medical Affairs, LLC, Beerse, Belgium, ⁷University of Glasgow, Glasgow, United Kingdom, ⁸Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: In the PsABio study (NCT02627768), real-world data from patients with PsA showed comparable clinical results after treatment with ustekinumab (UST, an anti-p40 IL-12/23 inhibitor)…
Abstract Number: 0478 • ACR Convergence 2020
Increasing Awareness of Advocacy During Early Career – a Web-Based Educational Program
Sirisha Gokaraju¹, Angus Worthing², Katherine Maher³, Grace Wright⁴ and Gail Kerr⁵, ¹Georgetown University hospital, Bethesda, MD, ²Arthritis & Rheumatism Associates, PC, Washington, DC, ³Arthritis & Rheumatism Associates, PC, Alexandria, VA, ⁴Association of Women in Rheumatology, New York, NY, ⁵Washington DC VA Medical Center, Washington, DC
Background/Purpose: In 2015, the American College of Rheumatology (ACR) began Advocacy 101 in person-education for Fellows in Training (FIT) and physicians to encourage participation in…
Abstract Number: 0643 • ACR Convergence 2020
Use of Biologic Treatment and Risk to Be Admitted for COVID-19 Infection
Carlos González¹, Luis Menchén¹, Indalecio Monteagudo¹, Ofelia Baniandrés², Juan Carlos Nieto Gonzalez¹, Ignacio Marín-Jiménez¹, Ana Herranz-Alonso¹, Carmen Lobo-Rodríguez¹, Amparo López-Esteban¹, Ana López¹, Arantza Ais-Larisgoitia¹, Esther Chamorro de Vega¹, Paloma Morales de los Ríos¹, Maria Jesús Lizcano¹, Jose Maria Alvaro-Gracia¹ and Sonia García de San-José¹, ¹CEIMI, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²CEIMI, Hospital General Universitario Gregorio Marañón, Madrid, Madrid, Spain
Background/Purpose: To analyze the risk of admission for COVID19 infection and outcome of patients treated with b/tsDMARD from our center, to compare with all patients…
Abstract Number: 0819 • ACR Convergence 2020
The Adherence Patterns Among Patients Using Infliximab Bio-originator and Biosimilar
Joseph Alanaeme¹, Sujith Sarvesh¹, Jeffrey R Curtis² and Huifeng Yun², ¹University of Alabama at Birmingham, BIrmingham, AL, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Infliximab (INF) biosimilar was approved for multiple indications in U.S. in 2016. Although clinical trials have demonstrated that switching from infliximab bio-originator to its…
Abstract Number: 0898 • ACR Convergence 2020
Inadequate Response Among Psoriatic Arthritis Patients Prescribed Advanced Therapy in a Real-world US Commercially Insured Population
Julie Birt¹, Michael Grabner², Keith Isenberg³, Theresa Hunter⁴, Chia-Chen Teng², Mingyang Shan¹, Jeffrey Lisse¹, Jianmin Wu¹, Kirstin Griffing¹ and Jeffrey R Curtis⁵, ¹Eli Lilly and Company, Indianapolis, IN, ²Healthcore, Inc, Wilmington, DE, ³Anthem, Inc, Indianapolis, IN, ⁴Eli Lilly and Company, Indianapolis, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The purpose of this analysis was to assess the frequency of inadequate response (IR) over 1 year associated with advanced therapy (AT) initiation among…
Abstract Number: 1210 • ACR Convergence 2020
Patient-Reported Outcomes Measurement Information System (PROMIS) Assessment of Response to Treatment with Golimumab IV or Infliximab in Rheumatoid Arthritis Patients: Results from a Phase 4 Study
Clifton Bingham III¹, Shelly Kafka², Shawn Black², Stephen Xu³, Wayne Langholff⁴ and Jeffrey R Curtis⁵, ¹Johns Hopkins University, Baltimore, MD, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Research & Development, LLC, Spring House, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: AWARE (Comparative & Pragmatic Study of Golimumab [GLM] Intravenous [IV] vs Infliximab [IFX] in RA) is a Phase 4 study designed to provide a…
Abstract Number: 1374 • ACR Convergence 2020
Secukinumab in the Treatment of Dactylitis in Patients with Psoriatic Arthritis: Post Hoc Analysis Results from a Randomized Phase 3 Trial
Bruce Kirkham¹, Peter Nash², Sandra Navarra³, Erhard Quebe-Fehling⁴, Corine Gaillez⁴, Carlos Sastre⁴ and Philip Mease⁵, ¹Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ²School of Medicine Griffith University, Brisbane, Queensland, Australia, ³University of Santo Tomas, Manila, Philippines, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: Dactylitis is a key and frequent clinical manifestation of psoriatic arthritis (PsA)1 associated with significant disease burden and impaired function.2–3 Randomized controlled trials designed…
Abstract Number: 1746 • ACR Convergence 2020
Association of Obesity with Treatment Response to Methotrexate or Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
Dilli Poudel¹, Ted Mikuls², Michael George¹, Bryant England², Grant Cannon³, Brian Sauer⁴ and Joshua Baker¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³Salt Lake City VA Medical Center and University of Utah, Salt Lake City, ⁴University of Utah, Omaha, NE
Background/Purpose: Obesity affects 30-40% of RA patients and is associated with higher clinical disease activity measures and progressive disability. Studies suggest that obesity may be…
Abstract Number: 2052 • ACR Convergence 2020
Extended Follow-Up of Patients Recruited to a Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-Associated Vasculitis and Relapsing Disease
Rona Smith¹, David Jayne² and Peter A. Merkel³, ¹University of Cambridge, Cambridge, United Kingdom, ²Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, ³Division of Rheumatology University of Pennsylvania, Philadelphia, PA
Background/Purpose: Rituximab is an effective therapy for induction of remission in ANCA-associated vasculitis (AAV). However, the effect of rituximab is not sustained, and subsequent relapse…
Abstract Number: 0222 • ACR Convergence 2020
tsDMARD Therapy Is Associated with More Initial Therapy Prolongations Compared to bDMARDs Both in Bionaive and Bioexperienced Patients with Rheumatoid Arthritis
Diederik De Cock¹, Patrick Durez², Dirk Elewaut³, Bernard Lauwerys⁴, Rene Westhovens⁵ and Patrick Verschueren⁶, ¹KU Leuven, Leuven, Belgium, ²Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, ³Ghent University and VIB, Heusden, Belgium, ⁴Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ⁵University Hospitals Leuven, Belgium, Leuven, Belgium, ⁶University Hospital Leuven, Leuven, Belgium
Background/Purpose: The Tool for Administrative Reimbursement Drug Information Sharing (TARDIS) is an electronic platform combining the collection of data from all Belgian patients with Rheumatoid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].